Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
THEOCLEAR L.A.-260 vs AEROLONE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Theophylline causes bronchodilation by inhibiting phosphodiesterase, increasing c AMP levels, and antagonizing adenosine receptors.
Selective beta2-adrenergic receptor agonist that relaxes bronchial smooth muscle by increasing cyclic AMP production via adenylate cyclase activation.
Treatment of symptoms and reversible airflow obstruction associated with chronic asthma,Chronic obstructive pulmonary disease (COPD)
Treatment of bronchospasm in patients with COPD,Long-term maintenance treatment of asthma
Theophylline (THEOCLEAR L. A.-260) 260 mg orally every 12 hours. Adjust dose based on serum theophylline concentrations to achieve 5-15 mcg/m L.
AEROLONE is not a recognized drug; no standard dosing available.
Terminal elimination half-life is approximately 6-12 hours in adults (range 3-12 hours, prolonged in congestive heart failure, liver disease, and with certain drugs). In neonates, half-life is prolonged (24-36 hours).
Terminal elimination half-life is approximately 12-15 hours in adults; prolonged to 24-30 hours in severe renal impairment (Cr Cl <30 m L/min).
Hepatic via CYP1A2, CYP2E1, and CYP3A4; undergoes N-demethylation and oxidation.
Primarily metabolized by CYP3A4 and to a lesser extent CYP2D6, with conjugation to inactive metabolites.
Renal elimination of unchanged drug (10%) and hepatic metabolism (90%). Metabolism is primarily via CYP1A2 and CYP3A4, with metabolites excreted in urine (about 80% of the dose) and feces (about 20%).
Primarily renal excretion of unchanged drug (approximately 65%) and hepatic metabolism (35%), with metabolites excreted in urine and feces. Biliary/fecal elimination accounts for <10%.
Approximately 40% bound to plasma proteins, primarily albumin.
Approximately 88% bound, primarily to albumin and alpha-1-acid glycoprotein.
Volume of distribution: 0.4-0.5 L/kg, indicating distribution into total body water. Higher Vd in neonates and patients with obesity.
3.5-5.0 L/kg, indicating extensive extravascular distribution and tissue binding.
Oral bioavailability: 96% to 100% for immediate-release formulations; sustained-release formulations have similar bioavailability but with prolonged absorption.
Oral: 35-50% (first-pass metabolism); Inhalation: 15-30% (dependent on device and technique); Intravenous: 100%.
No specific GFR-based dose adjustment recommended; however, monitor serum levels closely in renal impairment (Cr Cl <30 m L/min) due to potential accumulation of metabolites.
No data; not applicable.
Avoid use in Child-Pugh class C; for Child-Pugh class A or B, reduce dose by 50% and monitor serum concentrations.
No data; not applicable.
Children 6 months-9 years: Starting dose 12-14 mg/kg/day orally divided every 4-6 hours (immediate-release) or every 12 hours (sustained-release). Children 9-16 years: 12-14 mg/kg/day (max 900 mg/day) divided every 6-8 hours (immediate-release) or every 12 hours (sustained-release). Adjust to serum level 5-15 mcg/m L.
No data; not applicable.
Elderly patients (≥60 years): Start at 300 mg/day orally (sustained-release) in divided doses every 12 hours; titrate slowly, monitor serum levels, as clearance is reduced.
No data; not applicable.
No FDA black box warning.
None
Monitor serum theophylline levels to avoid toxicity; use with caution in patients with cardiac disease, seizure disorders, hepatic impairment, or COPD exacerbation; may interact with multiple drugs altering clearance.
Paradoxical bronchospasm,Cardiovascular effects (e.g., increased heart rate, QT prolongation),Hypokalemia,Hyperglycemia
Hypersensitivity to theophylline or any component; active seizure disorder not controlled by therapy.
Hypersensitivity to arformoterol or any component of the formulation
Avoid excessive intake of caffeine-containing foods and beverages (coffee, tea, cola, chocolate) as they may potentiate theophylline's CNS stimulant effects and toxicity. Concurrent ingestion of charcoal-broiled meats may increase theophylline clearance, potentially reducing efficacy. Grapefruit juice has been reported to increase theophylline levels; limit intake. A high-protein diet may increase clearance; maintain consistent dietary habits.
No significant food interactions. Avoid grapefruit juice as it may affect metabolism of the corticosteroid component.
Theophylline is not a major teratogen. First trimester: No increased risk of major malformations based on population data. Second and third trimesters: Use may be associated with transient neonatal toxemia (e.g., jitteriness, tachycardia, vomiting) if maternal levels are high near term. Risk of respiratory distress syndrome or neonatal apnea is theoretical only.
No evidence of teratogenicity in animal studies at doses up to 10 mg/kg/day (approximately 120 times the maximum recommended human daily inhaled dose). In humans, no controlled studies exist; however, data from postmarketing reports do not suggest an increased risk of structural anomalies. First trimester: limited data preclude definitive risk assessment, but no pattern of major birth defects has emerged. Second and third trimesters: no known fetal harm from inhaled doses; however, potential for fetal adrenal suppression with prolonged high-dose systemic exposure.
Theophylline is excreted into breast milk (M/P ratio approximately 0.6-0.7). Mean milk concentration is about 60-70% of maternal plasma. Relative infant dose is ~10% of maternal weight-adjusted dose. May cause irritability or insomnia in nursing infants, especially at high maternal doses. Benefits likely outweigh risks for asthma therapy, but monitor infant for signs of theophylline toxicity.
Unknown whether fluticasone propionate is excreted in human breast milk. Other corticosteroids are excreted in breast milk in low amounts, and inhaled doses result in negligible systemic levels, predicting unlikely significant infant exposure. M/P ratio not determined. Caution advised; weigh risk of maternal obstructive airway disease exacerbation against potential infant risks (adrenal suppression, growth retardation).
Pregnancy decreases theophylline clearance by 20-40% (especially third trimester). Dose may need reduction by 30-50% to maintain therapeutic levels, with close serum monitoring and adjustment every 2-4 weeks as pregnancy progresses. Smoking cessation (common in pregnancy) further reduces clearance and necessitates dose reduction.
No specific dose adjustment required based on pharmacokinetic changes; pregnancy may cause decreased airway reactivity but no significant changes in fluticasone clearance. Maintain lowest effective dose to control asthma. No dose increase recommended solely due to pregnancy. Monitor asthma control and adjust dose as per standard guidelines.
Theo-24 (theophylline extended-release) has a narrow therapeutic index (5-15 mcg/m L). Monitor serum levels due to significant interindividual variability in clearance. Avoid in patients with active peptic ulcer disease or seizure disorders unless absolutely necessary. Cimetidine, ciprofloxacin, and macrolides increase levels; smoking and rifampin decrease levels. Use with caution in heart failure, hepatic impairment, and elderly due to reduced clearance. For acute exacerbations, consider short-acting beta-agonists first.
AEROLONE is a combination inhaler containing an inhaled corticosteroid (fluticasone propionate) and a long-acting beta2-agonist (salmeterol). Advise patients to rinse mouth with water after each use to reduce risk of oral candidiasis. Not for acute bronchospasm; use a rescue inhaler (short-acting beta agonist) as needed. Monitor for increased heart rate, palpitations, or tremor. Do not stop abruptly; taper dose under medical supervision if discontinuing.
Take exactly as prescribed, do not crush or chew extended-release tablets.,Avoid sudden discontinuation; may require tapering.,Report symptoms of toxicity: nausea, vomiting, insomnia, jitteriness, palpitations, or seizures.,Limit caffeine intake (coffee, tea, cola, chocolate) as it may increase side effects.,Discuss all medications with your doctor, especially antibiotics and heartburn drugs (cimetidine, ciprofloxacin).,Do not smoke; smoking increases metabolism and may require dose adjustments.,If you miss a dose, take it as soon as remembered unless close to next dose; do not double up.
Use AEROLONE exactly as prescribed; do not exceed recommended dose.,Rinse your mouth with water after each use (do not swallow) to prevent thrush.,This medication is not for sudden breathing problems; always keep your rescue inhaler (e.g., albuterol) with you.,Do not stop using this medicine without talking to your doctor, as stopping suddenly may worsen your breathing.,Seek immediate medical help if you experience worsening asthma, chest pain, or allergic reaction.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about THEOCLEAR L.A.-260 vs AEROLONE, answered by our medical review team.
THEOCLEAR L.A.-260 is a Bronchodilator that works by Theophylline causes bronchodilation by inhibiting phosphodiesterase, increasing c AMP levels, and antagonizing adenosine receptors.. AEROLONE is a Bronchodilator that works by Selective beta2-adrenergic receptor agonist that relaxes bronchial smooth muscle by increasing cyclic AMP production via adenylate cyclase activation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between THEOCLEAR L.A.-260 and AEROLONE depend on the specific clinical indication. These are both Bronchodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of THEOCLEAR L.A.-260 is: Theophylline (THEOCLEAR L. A.-260) 260 mg orally every 12 hours. Adjust dose based on serum theophylline concentrations to achieve 5-15 mcg/m L.. The standard adult dose of AEROLONE is: AEROLONE is not a recognized drug; no standard dosing available.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between THEOCLEAR L.A.-260 and AEROLONE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. THEOCLEAR L.A.-260 is classified as Category C. Theophylline is not a major teratogen. First trimester: No increased risk of major malformations based on population data. Second and third trimesters: Use may be associated with t. AEROLONE is classified as Category C. No evidence of teratogenicity in animal studies at doses up to 10 mg/kg/day (approximately 120 times the maximum recommended human daily inhaled dose). In humans, no controlled stu. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.